Form 4 for RGNX REGENXBIO Inc.
Accepted 2025-03-31 00:00:00 ET · period of report 2025-03-27 · accession 0001562180-25-002804 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-31 | 2025-03-27 | RGNX | Mills Kenneth T. | Dir | M - OptEx | $3.76 | +30.8K | 475.1K | +7% | +$115.6K |
| D | 2025-03-31 | 2025-03-27 | RGNX | Mills Kenneth T. | Dir | M - OptEx | $0.00 | -30.8K | 20.6K | -60% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-27 | M | A | 30,752 | $3.76 | 475,103 | D | — | — | |
| 2 | Derivative | Stock Options (Right to Buy) | 2025-03-27 | M | D | 30,752 | $0.00 | 20,602 | D | $3.76 · — to 2025-05-19 | 30,752 Common Stock | (F1) The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter. |